Azenta Reschedules Fiscal 2022 Second Quarter Earnings Conference Call and Webcast

News provided by

Apr 28, 2022, 16:05 ET

CHELMSFORD, Mass., April 28, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has rescheduled the release of its earnings for the second fiscal quarter of 2022 which ended on March 31, 2022 from Tuesday, May 3, 2022 to Monday, May 9, 2022 after the market closes. The change is due to a delay in completing the quarter-end closing process related to the sale of the Semiconductor Automation business, which closed on February 1, 2022.

Azenta currently expects second quarter revenue and non-GAAP EPS to be within the previously issued guidance range.

The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, May 9, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-6194 for domestic callers and +1-212-231-2922 for international callers.

Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 10, 2022.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include but are not limited to statements about our revenue and earnings expectations. Factors that could cause results to differ from our expectations include the following: the impact of the COVID-19 global pandemic on the markets we serve, including our supply chain, and on the global economy generally, the volatility of the life sciences industries the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (Nasdaq: AZTA) from Brooks Automation, Inc, (Nasdaq: BRKS).

Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:

Sara Silverman
Director, Investor Relations
Azenta Life Sciences
978.262.2635
[email protected]

Sherry Dinsmore
Azenta Life Sciences
978.262.2400
[email protected]

SOURCE Azenta, Inc.